Paltoo D N, Canada R G
Department of Physiology and Biophysics, Howard University College of Medicine, Washington, DC 20059, USA.
Cancer Biochem Biophys. 1998 Oct;16(3):213-27.
In this investigation, we report a relationship between the terbium (Tb3+) binding protein and the cytotoxicity of cisplatin in human head and neck cancer cells. In the FaDu cell line, the cytotoxic action of cisplatin was shown to be approximately six times more potent than the cytotoxicity of Tb3+. When cisplatin was combined with 80 microM Tb3+, the IC20 and IC50 values for cisplatin were reduced by 70% and 24%, respectively. The IC80 value, however, was increased by 124%. The results suggest that the cytotoxicity of cisplatin is enhanced by Tb3+ at low cisplatin concentrations. In agreement with previous studies, calcium and cisplatin were found to be mixed-type and noncompetitive inhibitors, respectively, of the Tb3+ -FaDu intensity. These findings imply that the receptor binding of Tb3+ can modulate the cytotoxic activity of cisplatin.
在本研究中，我们报告了铽（Tb3+）结合蛋白与顺铂在人头颈部癌细胞中的细胞毒性之间的关系。在FaDu细胞系中，顺铂的细胞毒性作用显示出比Tb3+的细胞毒性大约强六倍。当顺铂与80微摩尔的Tb3+联合使用时，顺铂的IC20和IC50值分别降低了70%和24%。然而，IC80值增加了124%。结果表明，在低顺铂浓度下，Tb3+增强了顺铂的细胞毒性。与先前的研究一致，发现钙和顺铂分别是Tb3+ - FaDu强度的混合型和非竞争性抑制剂。这些发现意味着Tb3+的受体结合可以调节顺铂的细胞毒性活性。
